An integrating viral vector built on an HIV-1 backbone that efficiently infects both dividing and non-dividing cells — the mainstream tool for building stable cell lines and running long-term functional studies.
A 15-dimension comparison to help you decide based on your experimental goals
Lentivirus vectors are genetically engineered retroviral vectors built on the backbone of HIV-1 (Human Immunodeficiency Virus type 1). The name "lentivirus" comes from the slow disease course it causes in its natural host, but as a gene delivery tool its defining strength is exactly the opposite — fast, precise, and stable. It efficiently infects both dividing and non-dividing cells and integrates the gene of interest into the host genome for long-term, stable expression.
| Property | Description |
|---|---|
| Genome type | Single-stranded RNA, converted to DNA by reverse transcriptase and integrated into the host genome |
| Host cell range | Infects both dividing and non-dividing cells (its core advantage over ordinary retroviruses) |
| Expression profile | Integrates into the genome for long-term, stable expression — suited to building stable cell lines |
| Typical packaging capacity | Roughly 8kb or less (including regulatory elements) |
| Immunogenicity | Relatively low; further reduced by third-generation self-inactivating (SIN) design |
Lentivirus carries two copies of single-stranded RNA genome. After infecting a cell, the virus's own reverse transcriptase converts the RNA into double-stranded DNA, which is then inserted into the host cell's genome by integrase, becoming part of the host chromosome. It is precisely this "integration" step that lets the delivered gene of interest be stably replicated and expressed long-term as the cell divides — the fundamental feature that distinguishes lentivirus from "non-integrating" viral vectors such as adenovirus and AAV.
Early retroviral vectors retained the complete viral long terminal repeat (LTR), carrying a theoretical risk of insertional mutagenesis and activation of nearby proto-oncogenes. Third-generation lentiviral vectors adopt a "self-inactivating" (SIN) design — deleting the key enhancer/promoter sequences in the 3' LTR, so that after integration the LTR loses its transcriptional activation ability, substantially reducing insertional mutagenesis risk. This is now the mainstream design for research and clinical use.
To further improve safety, modern lentivirus production commonly uses a "split multi-plasmid" strategy: the transfer plasmid carrying the gene of interest, the packaging plasmid providing packaging proteins, and the envelope plasmid providing the envelope protein (typically VSV-G, which confers broad tropism) are kept separate and co-transfected into a packaging cell line (typically HEK293T). The advantage of this design is that the viral particle itself does not contain the full set of genetic elements needed to produce new virus, so even if it were to spread accidentally it could not self-replicate — making it far safer than early single-plasmid systems.
Italian scientist Luigi Naldini's team first reported a lentiviral vector built on an HIV-1 backbone, demonstrating that it could effectively infect non-dividing cells — a pioneering piece of work in lentiviral vector research.
Researchers progressively developed second- and third-generation lentiviral systems, continually improving safety by splitting packaging elements across separate plasmids and introducing the self-inactivating (SIN) design, gradually replacing earlier first-generation systems that carried higher biosafety concerns.
Lentiviral vectors have become one of the most widely used tools for building stable cell lines in vitro and studying gene function in vivo, and are further applied to gene delivery in cell-therapy fields such as CAR-T.
HIV-1 was chosen as the engineering backbone primarily because it naturally has the ability to infect non-dividing cells (such as neurons and resting immune cells) — a capability that ordinary retroviruses (such as Moloney murine leukemia virus, MLV) lack. After safety engineering, lentiviral vectors retain this core "infects non-dividing cells" advantage while removing the vast majority of genes required for pathogenicity, making it a safe and efficient gene delivery tool.
Lentivirus work must be carried out under BSL-2 (Biosafety Level 2) laboratory conditions. Operators must receive appropriate biosafety training, and waste must be inactivated according to protocol before disposal.
Sensitivity to lentivirus varies considerably across cell types. Before committing to a full experiment, we recommend a pilot run to determine the appropriate multiplicity of infection (MOI), avoiding cytotoxicity from an MOI that's too high or insufficient infection efficiency from one that's too low.
While the theoretical packaging capacity of lentivirus can reach about 10kb, we generally recommend keeping the combined length of the gene of interest plus regulatory elements under 8kb — exceeding this range will noticeably affect viral titer and packaging efficiency. If you genuinely need more, please discuss feasibility with a technical advisor in advance.
After lentiviral infection, cells need to go through drug selection (e.g. puromycin) and single-clone selection before a truly stable cell line is established. The overall process typically takes 3–6 weeks, so we recommend planning your experimental timeline in advance.
Lentivirus's pre-integration complex (PIC) can actively cross an intact nuclear envelope to enter the nucleus, whereas ordinary retroviruses depend on the temporary breakdown of the nuclear envelope during cell division to let the viral genome enter the nucleus — which is why they can only infect dividing cells.
VSV-G (vesicular stomatitis virus glycoprotein) recognizes receptors that are broadly present on the surface of nearly all mammalian cells, giving lentivirus "broad tropism" — the ability to infect almost any cell type. This is why VSV-G-pseudotyped lentivirus is so widely used.
No. Lentivirus integration sites are somewhat random across the genome (though with a preference for certain actively transcribed regions), which is also one source of insertional-mutagenesis risk — the third-generation SIN design exists precisely to reduce the safety risk this randomness creates.
Lentivirus is a genus within the broader family of retroviruses, and HIV belongs to this genus. All lentiviruses are retroviruses, but not all retroviruses are lentiviruses — the relationship is one of inclusion, not equivalence.